amoxicillin + clarithromycin + furazolidone

This is a combination therapy consisting of three antibiotics—amoxicillin, clarithromycin, and furazolidone. It is primarily used for the eradication of Helicobacter pylori infection, especially in cases where resistance to other antibiotics (such as metronidazole) is prevalent or when standard triple therapy has failed. - **Amoxicillin** is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis. - **Clarithromycin** is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. - **Furazolidone** is a nitrofuran antimicrobial agent with both antibacterial and antiprotozoal activity; it works by damaging bacterial DNA through reactive intermediates formed during its reduction. This combination targets H. pylori via multiple mechanisms, reducing the likelihood of resistance development and increasing eradication rates in populations with high resistance to other regimens[1][2]. The regimen may be considered as an alternative in regions where clarithromycin or metronidazole resistance limits standard therapies[2]. Furazolidone-containing regimens are more commonly used in developing countries due to cost-effectiveness but may have higher rates of side effects compared to some alternatives[1].

Other names

H. pylori triple therapyH. pylori triple therapy-Federal University of São Paulo-Helicobacter pylori infectionHelicobacter pylori triple therapy